Background: With the aging population and advancements in medical care worldwide, the number of older patients with end-stage kidney disease continues to rise. This study aimed to identify factors associated with osteoporosis and osteopenia in older patients undergoing incident hemodialysis and assess their impact on mortality. Methods: We analyzed a large multicenter retrospective cohort of patients aged ≥70 years undergoing incident hemodialysis to identify factors associated with osteoporosis using logistic regression analysis and to assess the association of death with osteoporosis and osteopenia using Cox multivariable analysis. Results: Among 710 patients, 39.0% and 19.6% had osteoporosis and osteopenia, respectively. Osteoporosis was significantly associated with female sex, a history of fractures, and the absence of phosphate binder use. During a median follow-up of 36.8 months, 348 participants (58.8%) died. Mortality rates were the highest in the osteoporosis group (79.8%), followed by the osteopenia (77.2%) and normal bone mineral density (BMD) groups (35.2%). Cox regression analysis revealed that even after adjusting for covariates, the osteoporosis group was significantly associated with a higher mortality risk than the normal BMD group. Osteoporosis at the start of hemodialysis was significantly associated with higher mortality. Conclusion We should consider the importance of bone health in patients undergoing incident hemodialysis and pay attention to the use of phosphate binders and fracture prevention.

Background and Objectives: Clinical characteristics and outcomes in acute heart failure (AHF) vary by phenotype. We assessed phenotype-specific features, treatment patterns, and outcomes in a nationwide Korean cohort. Methods: The Korean Heart Failure III registry prospectively enrolled 7,351 AHF admissions at 47 hospitals. Among 6,777 patients with available left ventricular ejection fraction (EF), phenotypes were defined as heart failure with reduced EF (HFrEF, ≤40%), mildly reduced EF (HFmrEF,41–49%), or preserved EF (HFpEF, ≥50%). The primary endpoint was a 12-month composite of all-cause death or heart transplantation, evaluated from index admission and, among hospital survivors, from discharge. We used inverse probability weighting (multinomial generalized boosted models with stabilized, trimmed weights) and weighted Cox proportional-hazards models to estimate hazard ratios (HRs). Results: Phenotype distribution was 58.9% HFrEF, 13.6% HFmrEF, and 27.5% HFpEF. Crude 12-month composite rates from index admission were 13.4% (HFrEF), 12.7% (HFmrEF), and 16.8% (HFpEF). After weighting, from index admission, HFmrEF (HR, 0.892; 95% confidence interval [CI], 0.731–1.088) and HFpEF (HR, 1.101; 95% CI, 0.939–1.291) did not differ from HFrEF; from discharge, HFpEF had modestly higher risk (HR, 1.207; 95% CI, 1.008–1.445) whereas HFmrEF did not (HR, 1.039; 95% CI, 0.844–1.279). Hyponatremia and chronic kidney disease were consistent adverse markers, while angiotensin-converting enzyme inhibitor/ angiotensin II receptor blocker use at discharge was protective. Conclusions Across the EF spectrum, phenotypes showed distinct profiles and risk. Postdischarge risk was modestly higher in HFpEF, supporting phenotype-tailored care and systematic discharge optimization in Korean patients with AHF.

In patients with differentiated thyroid cancer (DTC), initial recurrence risk stratification based on clinical, histopathological, and perioperative data remains the key determinant for guiding management strategies during the first 1-2 years post-treatment. However, the adoption of ongoing risk stratification (ORS), which dynamically reassesses risk by integrating longitudinal clinical data and treatment response, enables more precise long-term prognostic assessment and facilitates highly individualized management. Building upon recent guidelines, the 2026 KTA guideline has been further refined by incorporating robust evidence from large-scale national cohorts and comprehensive systematic reviews. These updated recommendations outline contemporary concepts of ORS, risk-adapted TSH suppression targets, optimized surveillance modalities for recurrence detection, and disease-specific long-term follow-up strategies. Reflecting the paradigm shift toward de-escalated treatment, this revision integrates evolved perspectives on TSH suppression intensity, the clinical interpretation of thyroglobulin levels, and tailored follow-up intervals. These evidence-based recommendations aim to minimize unnecessary treatment and excessive surveillance in the large proportion of patients with excellent prognosis after initial therapy, while ensuring that each patient receives appropriately tailored and effective long-term management.

Background and Objectives: In chronic heart failure (HF), natriuretic peptide (NP) levels are higher in atrial fibrillation (AF) compared to sinus rhythm (SR). However, due to the loss of atrial contraction, AF patients are prone to hemodynamic decompensation at earlier stages.Since NP levels reflect disease severity, acutely decompensated AF patients may exhibit lower NP levels compared to SR patients, who retain greater hemodynamic reserve. Methods: We analyzed 5,048 patients with acute HF from the Korea Acute Heart Failure registry with available NP data. NP levels and echocardiographic parameters were compared between AF and SR patients. The association of NP levels with in-hospital and one-year mortality was also assessed according to cardiac rhythm. Results: Brain natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were measured in 2,027 and 3,021 patients, respectively. NP levels were lower in AF than in SR (median BNP, 740 vs. 1,044 pg/mL; median NT-proBNP, 4,420 vs. 5,198 pg/mL), particularly in HF with reduced or mildly reduced ejection fraction. A similar trend was observed regardless of HF onset or etiology. AF patients had smaller left ventricular (LV) end-diastolic diameter and larger left atrial size compared to SR patients. Higher NP tertiles were associated with increased in-hospital and one-year mortality in both groups. Conclusions In acute HF, NP levels are lower in AF than in SR. AF patients also exhibited smaller LV chamber sizes. Nevertheless, NP levels remain strong predictors of outcomes in both AF and SR patients.

The increasing detection of papillary thyroid microcarcinoma (PTMC) has raised concerns about overtreatment.For low-risk PTMC, either immediate surgery or active surveillance (AS) can be considered. To support AS implementation, the Korean Thyroid Association convened a multidisciplinary panel and developed the first Korean guideline. AS is recommended to adults with pathologically proven Bethesda V-VI PTMC without clinical evidence of lymph node or distant metastasis, gross extrathyroidal extension, tracheal or recurrent laryngeal nerve invasion, or aggressive histology. Baseline assessment requires high‑resolution cervical ultrasound by experienced operators to rule out extrathyroidal extension, tracheal or recurrent laryngeal nerve invasion, and lymph node metastasis;contrast‑enhanced neck computed tomography is optional. Patient characteristics such as age, comorbidities, and capacity for long-term follow-up should be assessed. Shared decision-making should weigh the benefits and risks of surgery and AS, expected oncologic outcomes, complications, quality of life, anxiety, medical cost, and patient preference. Follow-up includes cervical ultrasound and thyroid function test every six months for two years, then annually. Disease progression, defined as significant tumor growth or newly detected nodal or distant metastasis, warrants surgery. Despite remaining uncertainties, this guideline offers a framework to ensure oncologic safety and support patient-centered active surveillance.

Purpose: This study aimed to develop a flexible eye shield phantom to acquire artifact-free computed tomography (CT) images for electron beam radiotherapy. Methods: A flexible eye shield phantom for a newly designed eye shield was fabricated. Because of metal artifacts caused by an eye shield composed of high-density materials such as tungsten or lead, CT image acquisition is not appropriate for treatment planning because of inaccurate dose calculation and organ-at-risk delineation. To acquire artifact-free CT images, a mold of the same size as the outer dimension of the metallic eye shield was manufactured using 3D printing. The flexible eye shield phantom was imaged using a Philips Brilliance CT Big Bore under the same condition as the measurement. The phantom image with an average of 200 Hounsfield unit (HU) was imported into the treatment planning systems (TPS) and assigned a value of 26,750 HU to consider the material density of tungsten. The dosimetric comparison using a 6-MeV electron beam was performed. Measurement was performed using a metal oxide semiconductor field effect transistor detector for point doses at 3 and 10 mm. Results: The artifact-free CT images using a flexible eye shield phantom without air bubbles were transferred into the TPS. The dose at 10 mm calculated using the TPS agreed with the ionchamber measurements within 2 cGy. Conversely, a larger dose discrepancy between the measured and calculated doses was found at 3 mm depth. Conclusions The flexible eye shield phantom was successfully fabricated to apply electron treatment planning by acquiring artifact-free CT images. The dose calculated using the artifact-free image was comparable to the measured dose at lens depth when applying an eye shield.

Purpose: This study aimed to develop a flexible eye shield phantom to acquire artifact-free computed tomography (CT) images for electron beam radiotherapy. Methods: A flexible eye shield phantom for a newly designed eye shield was fabricated. Because of metal artifacts caused by an eye shield composed of high-density materials such as tungsten or lead, CT image acquisition is not appropriate for treatment planning because of inaccurate dose calculation and organ-at-risk delineation. To acquire artifact-free CT images, a mold of the same size as the outer dimension of the metallic eye shield was manufactured using 3D printing. The flexible eye shield phantom was imaged using a Philips Brilliance CT Big Bore under the same condition as the measurement. The phantom image with an average of 200 Hounsfield unit (HU) was imported into the treatment planning systems (TPS) and assigned a value of 26,750 HU to consider the material density of tungsten. The dosimetric comparison using a 6-MeV electron beam was performed. Measurement was performed using a metal oxide semiconductor field effect transistor detector for point doses at 3 and 10 mm. Results: The artifact-free CT images using a flexible eye shield phantom without air bubbles were transferred into the TPS. The dose at 10 mm calculated using the TPS agreed with the ionchamber measurements within 2 cGy. Conversely, a larger dose discrepancy between the measured and calculated doses was found at 3 mm depth. Conclusions The flexible eye shield phantom was successfully fabricated to apply electron treatment planning by acquiring artifact-free CT images. The dose calculated using the artifact-free image was comparable to the measured dose at lens depth when applying an eye shield.

With advancements in both pharmacologic and non-pharmacologic treatments, significant changes have occurred in heart failure (HF) management. The previous Korean HF registries, namely the Korea Heart Failure Registry (KorHF-registry) and Korean Acute Heart Failure Registry (KorAHF-registry), no longer accurately reflect contemporary acute heart failure (AHF) patients. Our objective is to assess contemporary AHF patients through a nationwide registry encompassing various aspects, such as clinical characteristics, management approaches, hospital course, and long-term outcomes of individuals hospitalized for AHF in Korea. This prospective observational multicenter cohort study (KorHF III) is organized by the Korean Society of Heart Failure. We aim to prospectively enroll 7,000 or more patients hospitalized for AHF at 47 tertiary hospitals in Korea starting from March 2018. Eligible patients exhibit signs and symptoms of HF and demonstrate either lung congestion or objective evidence of structural or functional cardiac abnormalities in echocardiography, or isolated right-sided HF. Patients will be followed up for up to 5 years after enrollment in the registry to evaluate long-term clinical outcomes. KorHF III represents the nationwide AHF registry that will elucidate the clinical characteristics, management strategies, and outcomes of contemporary AHF patients in Korea.

Purpose: This study aimed to develop a flexible eye shield phantom to acquire artifact-free computed tomography (CT) images for electron beam radiotherapy. Methods: A flexible eye shield phantom for a newly designed eye shield was fabricated. Because of metal artifacts caused by an eye shield composed of high-density materials such as tungsten or lead, CT image acquisition is not appropriate for treatment planning because of inaccurate dose calculation and organ-at-risk delineation. To acquire artifact-free CT images, a mold of the same size as the outer dimension of the metallic eye shield was manufactured using 3D printing. The flexible eye shield phantom was imaged using a Philips Brilliance CT Big Bore under the same condition as the measurement. The phantom image with an average of 200 Hounsfield unit (HU) was imported into the treatment planning systems (TPS) and assigned a value of 26,750 HU to consider the material density of tungsten. The dosimetric comparison using a 6-MeV electron beam was performed. Measurement was performed using a metal oxide semiconductor field effect transistor detector for point doses at 3 and 10 mm. Results: The artifact-free CT images using a flexible eye shield phantom without air bubbles were transferred into the TPS. The dose at 10 mm calculated using the TPS agreed with the ionchamber measurements within 2 cGy. Conversely, a larger dose discrepancy between the measured and calculated doses was found at 3 mm depth. Conclusions The flexible eye shield phantom was successfully fabricated to apply electron treatment planning by acquiring artifact-free CT images. The dose calculated using the artifact-free image was comparable to the measured dose at lens depth when applying an eye shield.

Purpose: This study aimed to develop a flexible eye shield phantom to acquire artifact-free computed tomography (CT) images for electron beam radiotherapy. Methods: A flexible eye shield phantom for a newly designed eye shield was fabricated. Because of metal artifacts caused by an eye shield composed of high-density materials such as tungsten or lead, CT image acquisition is not appropriate for treatment planning because of inaccurate dose calculation and organ-at-risk delineation. To acquire artifact-free CT images, a mold of the same size as the outer dimension of the metallic eye shield was manufactured using 3D printing. The flexible eye shield phantom was imaged using a Philips Brilliance CT Big Bore under the same condition as the measurement. The phantom image with an average of 200 Hounsfield unit (HU) was imported into the treatment planning systems (TPS) and assigned a value of 26,750 HU to consider the material density of tungsten. The dosimetric comparison using a 6-MeV electron beam was performed. Measurement was performed using a metal oxide semiconductor field effect transistor detector for point doses at 3 and 10 mm. Results: The artifact-free CT images using a flexible eye shield phantom without air bubbles were transferred into the TPS. The dose at 10 mm calculated using the TPS agreed with the ionchamber measurements within 2 cGy. Conversely, a larger dose discrepancy between the measured and calculated doses was found at 3 mm depth. Conclusions The flexible eye shield phantom was successfully fabricated to apply electron treatment planning by acquiring artifact-free CT images. The dose calculated using the artifact-free image was comparable to the measured dose at lens depth when applying an eye shield.